26.09.2019 2019 Half-year consolidated results: Deinove’s progress coming to fruition Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...
09.07.2019 Issuance of notes convertible into new shares for a maximum amount of €15M. Issuance of a first €2.2 million tranche DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
28.03.2019 2018 Annual Results: a year of significant progress Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...
21.11.2018 DEINOVE confirms its financing options by renewing its equity line The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...
27.09.2018 2018 half-year consolidated results: strengthened financial situation, substantial progress in both areas of business Cash position: +€9.9m at June 30, 2018 compared to +€4.9m at December 31, 2017 thanks to the reinforcement of shareholders' equity Half-...
15.06.2018 DEINOVE: Successful capital increase of € 8.5 million Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...
23.05.2018 General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...
13.04.2018 DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...
29.03.2018 2017: ambitions confirmed, milestones reached, and financial results in line with the development strategy Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...
28.09.2017 2017 half-year consolidated results: stability of net loss major progress on R&D programs in health, nutrition and cosmetics Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...